Peripheral Neuropathy News and Research

RSS
Peripheral neuropathy describes damage to the peripheral nervous system, which transmits information from the brain and spinal cord to every other part of the body.

More than 100 types of peripheral neuropathy have been identified, each with its own characteristic set of symptoms, pattern of development, and prognosis. Impaired function and symptoms depend on the type of nerves -- motor, sensory, or autonomic -- that are damaged. Some people may experience temporary numbness, tingling, and pricking sensations, sensitivity to touch, or muscle weakness. Others may suffer more extreme symptoms, including burning pain (especially at night), muscle wasting, paralysis, or organ or gland dysfunction. Peripheral neuropathy may be either inherited or acquired. Causes of acquired peripheral neuropathy include physical injury (trauma) to a nerve, tumors, toxins, autoimmune responses, nutritional deficiencies, alcoholism, and vascular and metabolic disorders. Acquired peripheral neuropathies are caused by systemic disease, trauma from external agents, or infections or autoimmune disorders affecting nerve tissue. Inherited forms of peripheral neuropathy are caused by inborn mistakes in the genetic code or by new genetic mutations.
Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Entelos' T1D PhysioLab platform published in Clinical and Experimental Immunology

Entelos' T1D PhysioLab platform published in Clinical and Experimental Immunology

Competitive Technologies to raise over $5M to accelerate sales of Calmare Pain Therapy Treatment

Competitive Technologies to raise over $5M to accelerate sales of Calmare Pain Therapy Treatment

US District Court dismisses all claims and counterclaims in thalidomide patent cases

US District Court dismisses all claims and counterclaims in thalidomide patent cases

Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept

Targeted enrollment in Phase IIb trial for EpiCept NP-1 in CPN attained: EpiCept

Combination therapy improves patients with depression symptoms: Study

Combination therapy improves patients with depression symptoms: Study

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

Enrollment in phase II clinical trial of brentuximab vedotin for ALCL completed

CTT's Calmare Pain Therapy Treatment decreases pain associated with CIPN

CTT's Calmare Pain Therapy Treatment decreases pain associated with CIPN

The Neuropathy Association joins with the Empire State Building to recognize National Neuropathy Week

The Neuropathy Association joins with the Empire State Building to recognize National Neuropathy Week

UCF receives $1.9M NIH grant for exploring new ways of reversing damage caused by MS

UCF receives $1.9M NIH grant for exploring new ways of reversing damage caused by MS

Study results of CTT's Calmare Pain Therapy for CIPN to be presented

Study results of CTT's Calmare Pain Therapy for CIPN to be presented

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

Takeda enters co-promotion agreement with Janssen Pharma for VELCADE

EpiCept provides update on corporate strategy, reports net loss of $4.5M for first-quarter 2010

EpiCept provides update on corporate strategy, reports net loss of $4.5M for first-quarter 2010

New data on Cimzia for Crohn’s Disease treatment to be demonstrated at DDW 2010

New data on Cimzia for Crohn’s Disease treatment to be demonstrated at DDW 2010

Study evaluates cost benefits of new interventions for treating, preventing PDN and PHN

Study evaluates cost benefits of new interventions for treating, preventing PDN and PHN

DARA Therapeutics collaborates to advance clinical study of KRN5500 for CIPN in cancer patients

DARA Therapeutics collaborates to advance clinical study of KRN5500 for CIPN in cancer patients

Phase II clinical study examining CTT's Calmare pain therapy medical device completed

Phase II clinical study examining CTT's Calmare pain therapy medical device completed

Competitive Technologies to introduce Calmare pain therapy at medical conference

Competitive Technologies to introduce Calmare pain therapy at medical conference

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

FDA grants "Fast Track" designation for Genta’s advanced gastric cancer drug tesetaxel

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

Genta commences Phase 2b trial of tesetaxel in patients with advanced gastric cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.